The cost-effectiveness of treatment with desloratadine in patients with persistent allergic rhinitis

Abstract

Objectives:

A new classification of persistent allergic rhinitis (PER) has been developed by the ARIA working group. Although the burden of AR is significant, treatment itself is also costly. It is unclear if treatment based on the new definition of PER is cost-effective.